NCT05166239 2026-01-23
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
Peking University
Phase 2 Completed
Clinical Trials
14 trialsNCT06980350 2025-07-29
Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy
Sun Yat-sen University
Completed
NCT07009600 2025-06-06
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Samsung Medical Center
Completed
NCT06991907 2025-05-28
PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety
Jiangxi Provincial Cancer Hospital
Phase NA Completed
NCT06900686 2025-03-28
Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival
Sun Yat-sen University
Completed
NCT04721223 2024-09-19
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT03817736 2024-05-09
START-FIT
The University of Hong Kong
Phase 2 Completed
NCT06031376 2023-09-11
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Hunan Cancer Hospital
Completed
NCT06022692 2023-09-05
HEAIS001
Zhejiang Hospital
Phase 1/2 Completed
NCT06011330 2023-08-30
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer
Hunan Cancer Hospital
Completed
NCT05942768 2023-07-12
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Hunan Cancer Hospital
Completed
NCT05535998 2022-09-10
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT
Sun Yat-sen University
Completed
NCT05307926 2022-09-07
Postoperative Adjuvant Therapy of HCC Based on PD-1
Tongji Hospital
Completed
NCT05489692 2022-08-10
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Completed